SA
CRL icon

Shilanski & Associates’s Charles River Laboratories CRL Stock Holding History

Shilanski & Associates’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-3,284
Closed -$1.24M – 130
2021
Q4 		$1.24M Sell
3,284
-13
-0.4% -$5.05K 0.53% 53
2021
Q3 		$1.36M Buy
+3,297
New +$1.37M 0.63% 48

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Shilanski & Associates's CRL Position: Q1 2022 in Review

Shilanski & Associates sold out of Charles River Laboratories (CRL) in Q1 2022, closing a stake of 3,284 shares — an estimated $1.24M sold.

Shilanski & Associates first reported a position in CRL in Q3 2021 and held it in 2 quarters. The position peaked at $1.36M in Q3 2021. 644 funds tracked by Wall St. Rank hold CRL as of Q1 2022.

  • Shilanski & Associates reported no remaining Charles River Laboratories position as of Q1 2022 after selling out during the quarter.
  • Shilanski & Associates sold 3,284 Charles River Laboratories shares in Q1 2022, an estimated $1.24M.
  • Shilanski & Associates first reported a position in Charles River Laboratories in Q3 2021 and held it in 2 quarters.
  • Shilanski & Associates's Charles River Laboratories position peaked at $1.36M in Q3 2021.
  • 644 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2022.

Based on Shilanski & Associates's 13F filing for Q1 2022, filed 20 Apr 2022.